Why Researchers are Taking a Diverse Approach to Alzheimer’s Disease
Published on:
Today, Alzheimer's research isn't limited to just a few possibilities. University researchers and pharmaceutical companies large and small are exploring a range of treatment opportunities. Antidote caught up with Keith W. Whitaker, PhD, Director of Scientific Programs, Neuroscience, at the BrightFocus Foundation for his take on the latest – and why clinical trial participation is so critical to the process.